Clinical Trial Update: Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 [Phase 1, Phase 2]

View source ↗

Summary

Open-label Phase 1/2 trial of Pocenbrodib alone and in combination with Abiraterone acetate, Olaparib, or 177Lu-PSMA-617 is currently recruiting for metastatic …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Olaparib (Olaparib)
• Pluvicto (lutetium-177 PSMA-617)
• Pocenbrodib

Snippet

Sponsor: Pathos AI, Inc. | Conditions: mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Neoplasms, Male | Phase 1, Phase 2 | Status: RECRUITING